Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Banneau, Guillaume ^a   Guedj, Mickaël ^b   MacGrogan, Gaëtan ^a,c   de Mascarel, Isabelle ^c   Velasco, Valerie ^c   Schiappa, Renaud ^b   Bonadona, Valerie ^d   David, Albert ^e   Dugast, Catherine ^f   Gilbert Dussardier, Brigitte ^g   Ingster, Olivier ^h   Vabres, Pierre ⁱ   Caux, Frederic ^j   de Reynies, Aurelien ^b   Iggo, Richard ^a   Sevenet, Nicolas ^a,c   Bonnet, Françoise ^a,c   Longy, Michel ^a,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Ligue Nationale Contre le Cancer ^*  (France)

^c INSTITUT BERGONIÉ   (France)

^d CENTRE LÉON BÉRARD   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h ANGERS UNIVERSITY HOSPITAL   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j AVICENNE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GAMMA GLUTAMYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; CONTROLLED STUDY; COWDEN SYNDROME; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL TUMOR; DNA MICROARRAY; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS;

BREAST NEOPLASMS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION PROFILING; GERM-LINE MUTATION; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PRINCIPAL COMPONENT ANALYSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 78650909068     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2626     Document Type: Article

References (54)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
5. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, Eyfjord JE. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009, 11:R47. 10.1186/bcr2334, 2750106, 19589159.
6. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboue B, Lin AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A, Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP, Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998, 7:507-515. 10.1093/hmg/7.3.507, 9467011.
7. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MM, Easton DF, Eeles RA, Hodgsen S, Mulvihill JJ, Murday VA, Tucker MA, Mariman EC, Starink TM, Ponder BA, Ropers HH, Kremer H, Longy M, Eng C. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996, 13:114-116. 10.1038/ng0596-114, 8673088.
8. Starink TM, van der Veen JP, Arwert F, de Waal LP, de Lange GG, Gille JJ, Eriksson AW. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986, 29:222-233. 10.1111/j.1399-0004.1986.tb00816.x, 3698331.
9. ArrayExpress. , http://www.ebi.ac.uk/microarray-as/ae/
10. CIT. , http://cit.ligue-cancer.net/index.php/en
11. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Sanson M, Delattre JY, Thomas G, Hamelin R. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999, 84:150-154. 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#, 10096247.
12. Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM, Saurin JC, Puisieux A, Olschwang S, Frebourg T. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 2000, 60:2760-2763.
13. Integragen. , http://www.integragen.com
14. CAPWeb. , http://bioinfo-out.curie.fr/CAPweb/
15. VAMP. , http://bioinfo.curie.fr/vamp
16. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, Manie E, Brennetot C, Janoueix-Lerosey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delattre O, Aurias A, Radvanyi F, Barillot E. VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006, 22:2066-2073. 10.1093/bioinformatics/btl359, 16820431.
17. R-project - V2.9.1. , http://www.R-project.org
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
19. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
20. BRB ArrayTools. , http://linus.nci.nih.gov/BRB-ArrayTools.html
21. Robustness. , http://genome-www.stanford.edu/breast_cancer/robustness
22. Guedj M, Robin S, Celisse A, Nuel G. Kerfdr: a semi-parametric kernel-based approach to local false discovery rate estimation. BMC Bioinformatics 2009, 10:84. 10.1186/1471-2105-10-84, 2679733, 19291295.
23. Breiman L. Random forests. Machine Learning 2001, 45:5-32.
24. EBI FTP Server. , ftp://ftp.ebi.ac.uk/pub/databases/GO/goa
25. MSigDB. , http://www.broadinstitute.org/gsea/msigdb
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
27. Dray S, Dufour AB. The ade4 package: implementing the duality diagram for ecologists. Journal of Statistical Software 2007, 22:1-20.
28. Fraley C, Raftery AE. Model-based clustering, discriminant analysis, and density estimation. Journal of the American Statistical Association 2002, 97:611-631.
29. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
30. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
31. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
32. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:E7. 10.1371/journal.pbio.0020007, 314300, 14737219.
33. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671. 10.1038/sj.onc.1208561, 15897907.
34. Vranic S, Tawfik O, Palazzo J, Bilalovic J, Eyzaguirre E, Lee LMJ, Adegboyega P, Hagenkord J, Gatalica Z. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010, 23:644-653. 10.1038/modpathol.2010.50, 20208479.
35. Mazoujian G, Pinkus GS, Davis S, Haagensen DE. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983, 110:105-112. 1916150, 6130702.
36. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008. 10.1038/sj.onc.1209415, 16491124.
37. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008, 10:542-548. 2386539, 18516291.
38. Celis JE, Cabezon T, Moreira JM, Gromov P, Gromova I, Timmermans-Wielenga V, Iwase T, Akiyama F, Honma N, Rank F. Molecular characterization of apocrine carcinoma of the breast: Validation of an apocrine protein signature in a well-defined cohort. Mol Oncol 2009,
39. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 2008, 52:3-10. 10.1111/j.1365-2559.2007.02888.x, 18171412.
40. Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jumppanen M, Staaf J, Jonsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008, 40:102-107. 10.1038/ng.2007.39, 18066063.
41. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998, 29:47-53. 10.1016/S0046-8177(98)90389-6, 9445133.
42. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Similarities of cutaneous and breast pathology in Cowden's Syndrome. Exp Dermatol 1998, 7:380-390. 10.1111/j.1600-0625.1998.tb00338.x, 9858141.
43. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mut 2000, 16:109-122. 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0, 10923032.
44. COSMIC - Catalogue of Somatic Mutations in Cancer. , http://www.sanger.ac.uk/perl/genetics/CGP/cosmic/
45. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdes A, Gestraud P, Hupe P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10:R101. 10.1186/bcr2204, 2656897, 19055754.
46. Lin HK, Hu YC, Lee DK, Chang C. Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol Endocrinol 2004, 18:2409-2423. 10.1210/me.2004-0117, 15205473.
47. Nan B, Snabboon T, Unni E, Yuan J, Whang YE, Marcelli M. The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. J Mol Endocrinol 2003, 31:169-183. 10.1677/jme.0.0310169, 12914534.
48. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004, 6:517-527. 10.1016/j.ccr.2004.09.031, 15542435.
49. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 2003, 100:8933-8938. 10.1073/pnas.1537685100, 166416, 12853564.
50. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402. 10.1016/j.ccr.2007.08.030, 17936563.
51. Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD, Muller WJ. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008, 68:2122-2131. 10.1158/0008-5472.CAN-07-5727, 2752841, 18381417.
52. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001, 11:764-768. 10.1016/S0960-9822(01)00225-1, 11378386.
53. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 2006, 118:2390-2398. 10.1002/ijc.21799, 16425225.
54. Lim E, Vaillant F, Wu D, Forrest NC, Bhupinder P, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ; K, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-915. 10.1038/nm.2000, 19648928.